APA (7th ed.) Citation

S, S., P, G., RC, S., L, M., A, M., C, B., . . . E, C. (2026). Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer. Cell death discovery, 12(1), 86. https://doi.org/10.1038/s41420-026-02940-3

Chicago Style (17th ed.) Citation

S, Sabbioni, et al. "Targeting Metabolic Vulnerabilities: REV-ERB Agonist SR9009 Potentiates Sorafenib Efficacy in Liver Cancer." Cell Death Discovery 12, no. 1 (2026): 86. https://doi.org/10.1038/s41420-026-02940-3.

MLA (9th ed.) Citation

S, Sabbioni, et al. "Targeting Metabolic Vulnerabilities: REV-ERB Agonist SR9009 Potentiates Sorafenib Efficacy in Liver Cancer." Cell Death Discovery, vol. 12, no. 1, 2026, p. 86, https://doi.org/10.1038/s41420-026-02940-3.